Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSM-779690T in healthy volunteers
NCT07155980Phase 1Withdrawn
- Sponsor
- ACTA Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSM-779690T in Alzheimer's disease (AD) (10 cohorts), sponsored by ACTA Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at 21 days. Planned start Nov 2025; status: withdrawn.
02
Drugs
GSM-779690T
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07155980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07155980.